Hair thinning affects both men and women, with female hair loss, especially during perimenopause and menopause, showing a significant increase and causing considerable distress. Existing treatments include topical minoxidil, platelet-rich plasma (PRP) combined with low-level light therapy, and oral medications like minoxidil and finasteride. Oral minoxidil, initially for blood pressure, can have side effects like dizziness due to its quick peak and drop in the bloodstream, limiting its effectiveness for hair growth. Emerging treatments offer new hope. Baridermix is developing an extended-release oral minoxidil at a higher dosage, designed to maintain therapeutic levels longer without significant blood pressure fluctuations, potentially leading to triple the hair growth. Additionally, Absci, an artificial intelligence company, is creating a blocker for the prolactin receptor on hair follicles, which could convert vellus (baby) hairs into actively growing hairs. These innovative products are currently in clinical trials, signaling significant advancements in hair growth solutions.